Novartis signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.
Novartis said the Committee for Medicinal Products for Human Use approved a label update for Cosentyx (secukinumab), the first interleukin-17A approved to treat psoriasis.
Biopharmaceutical company Celgene Corp. will buy a stake in BeiGene Ltd. and help develop and commercialize BeiGene’s investigational treatment for tumor cancers.
The threat of slowing demand and new competition in GlaxoSmithKline’s flagship HIV drug business unnerved investors in Britain’s biggest drugmaker, sending its shares down as much as 1.8 percent.
AgileHealthInsurance.com released the results of a nationwide poll that revealed an overwhelming majority of Americans desire additional health plan choices alongside Obamacare.
Array BioPharma filed NDAs for binimetinib 45 mg twice daily and encorafenib 450 mg once daily for BRAF-mutant advanced, unresectable or metastatic melanoma.
Bristol-Myers Squibb announced promising interim data from its Phase III clinical trial of Opdivo 3 mg/kg compared to 10 mg/kg Yervoy in melanoma.
Tokyo-based Daiichi Sankyo Company announced that it was ending its development deal of CHS-0214 with Coherus Biosciences.
The struggling Massachusetts-based company terminated five employees, about 63 percent of its workforce, as a part of a cost-cutting effort. The job cuts leaves the company with three employees, according to the Boston Business Journal. Stock prices tumbled more than 50 percent after the company made the announcement, closing at 29 cents per share.
British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.
Support Info-Go, the leading provider of health condition event listings, wants cancer patients to know they are not alone and celebrate independence from their condition with the launch of Cancer-Go.
A definitive merger agreement was signed under which the shareholders of privately held Innovate Biopharmaceuticals Inc. will become the majority owners of Monster Digital Inc. Subject to shareholder approval, the combined company will advance a late-stage drug for celiac disease, which Innovate believes is a significant unmet medical need, into expected Phase 3 clinical trials.
Japan’s Ministry of Health, Labor and Welfare granted marketing approval for Olumiant (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis.
A brain training computer game developed by British neuroscientists has been shown to improve the memory of patients in the very earliest stages of dementia and could help such patients avert some symptoms of cognitive decline.